Fig. 2

Higher ACE2 protein and mRNA levels in parietal cortex of AD participants from the second cohort. AD subjects from Cohort #2 had higher levels of ACE2 protein and mRNA compared to controls. Diagnosis was determined using Braak staging. ACE2 levels were determined by Western blotting after SDS-PAGE (10% acrylamide) and qPCR analysis A, B. Statistical analysis: Mann–Whitney test *p < 0.05, Unpaired t-test **p < 0.01. All samples, loaded in a random order, were run on the same immunoblot experiment for quantification. Examples were taken from the same immunoblot experiment, and consecutive bands loaded in random order are shown. GAPDH is shown as a loading control. Data are represented as a scatterplot. Horizontal lines indicate mean ± SEM. A Alzheimer’s disease (Braak scores III-VI), ACE2 Angiotensin-Converting Enzyme 2, C Control (Braak scores I or II), Dx Diagnostic, GAPDH Glyceraldehyde-3-phosphate dehydrogenase, O.D. Optical Density, SEM standard error of the mean